Related Experiment Video
Updated: Jun 21, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Telaprevir: hope on the horizon, getting closer
Ilan S Weisberg1, Ira M Jacobson
1Division of Gastroenterology and Hepatology, Department of Medicine, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York Presbyterian Hospital, NY 10021, USA.
Clinics in Liver Disease
|July 25, 2009
Summary
Telaprevir, a protease inhibitor, improves sustained virologic response rates for hepatitis C virus (HCV) infection when added to standard therapy. This new treatment is well-tolerated and shortens treatment duration for chronic HCV patients.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Standard therapy for chronic hepatitis C virus (HCV) infection, using pegylated interferon and ribavirin, has limited efficacy (40-50%) in genotype 1 patients and causes significant toxicities.
- Novel small molecule inhibitors targeting essential HCV replication enzymes are under development.
Purpose of the Study:
- To review the current experience and efficacy of telaprevir, a protease inhibitor, in treating chronic HCV infection.
- To evaluate telaprevir's use as monotherapy and in combination with other agents.
Main Methods:
- Review of clinical trial data for telaprevir in chronic HCV infection.
- Assessment of telaprevir's safety and tolerability in combination with standard therapy.
Main Results:
- Telaprevir, an inhibitor of the HCV NS3/4A protease, shows promise in early trials and advanced clinical development.
- Addition of telaprevir to standard interferon and ribavirin therapy enhances sustained virologic response rates in treatment-naïve and previously treated patients.
- Combination therapy with telaprevir is well-tolerated and allows for shorter treatment durations.
Conclusions:
- Telaprevir represents a promising therapeutic option for chronic HCV infection, improving treatment outcomes.
- Combination therapy with telaprevir offers enhanced efficacy and improved tolerability compared to standard therapy alone.
- Further review of telaprevir's role in monotherapy and combination regimens is warranted.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:29Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...